Combination Strategies to Improve Targeted Radionuclide Therapy.

ABSTRACT: In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation to tumors in a targeted manner, reducing the dose that healthy tissues are exposed to. Existing TRT strategies include the use of ¹⁷⁷Lu-DOTATATE, ¹³¹I-metaiodobenzylguanidine, Bexxar, and Zevalin, clinically approved agents for the treatment of neuroendocrine tumors, neuroblastoma, and non-Hodgkin lymphoma, respectively. Although promising results have been obtained with these agents, clinical evidence acquired to date suggests that only a small percentage of patients achieves complete response. Consequently, there have been attempts to improve TRT outcomes through combinations with oth

SUBMITTER: Chan TG 

PROVIDER: S-EPMC8679619 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature